<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00324961</url>
  </required_header>
  <id_info>
    <org_study_id>ADF106632</org_study_id>
    <nct_id>NCT00324961</nct_id>
  </id_info>
  <brief_title>Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B</brief_title>
  <official_title>A 2-year Multi-centre, Open-label, Local Phase IV Study to Demonstrate the Efficacy and Safety of Adefovir Dipivoxil Tablets (10mg) in Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is a phase IV, 2-year, multi-center, single arm and open-label study, evaluating the
      efficacy and safety with using local manufactured adefovir dipivoxil in Chinese subjects with
      HBeAg negative chronic hepatitis B
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving HBV DNA ≤300 Copies/mL at Week 104</measure>
    <time_frame>Week 104</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Histological Improvement After the 104-week Treatment</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Histology Scores in HBeAg Negative Participants With Two Sequential Liver Biopsies During the Period of 104 Weeks</measure>
    <time_frame>Baseline to Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Median Serum HBV DNA Over Time</measure>
    <time_frame>Baseline and Weeks 13, 26, 39, 52, 65, 78, 91, and 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving ALT Normalization at Week 104</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving HBsAg Loss and HBsAg Seroconversion at Week 104</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ADV-associated Resistance at Week 104</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving HBV DNA ≤300 Copies/mL Over Time</measure>
    <time_frame>Weeks 13, 26, 39, 52, 65, 78, 91, and 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Complete Response at Week 104</measure>
    <time_frame>Week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Protocol-defined Complete Response Over a 104-week Treatment Period</measure>
    <time_frame>Baseline to Week 104</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">533</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Single arm open label adefovir dipivoxil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adefovir dipivoxil once daily 10 mg orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adefovir dipivoxil tablets</intervention_name>
    <description>adefovir dipivoxil once daily 10 mg orally</description>
    <arm_group_label>Single arm open label adefovir dipivoxil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged 18‑65 years inclusive

          -  Documented chronic hepatitis B infection determined by the presence of serum HBsAg for
             at least 6 months

          -  Documented HBeAg negative and HBeAb positive at the screening visit and with at least
             a 6 months history of HBeAg negativity.

          -  Serum HBV DNA ≥ 104 copies/mL (Roche COBAS AMPLICORTM HBV MONITOR Test, LLOD 300
             copies/mL) at study screening (within 4 weeks before baseline)

          -  ALT value ≥1.3 times the upper limit of normal (ULN) at the time of screening, as
             determined using laboratory ranges and documented ALT abnormal within 6 month prior to
             the study screening.

          -  Serum alpha fetoprotein (AFP) &lt; 50 ng/mL at the first screening visit. If the AFP
             level is ≥ 50 ng/mL but declined to &lt; 50 ng/mL between screening and baseline, the
             patient is eligible.

          -  Compensated liver disease with the following laboratory and clinical parameters at
             study screening:

               -  Prothrombin time ≤ 2 second above normal range.

               -  Albumin ≥ 35 g/L.

               -  Total bilirubin ≤ 2.5 mg/dL (≤ 43 µmol/L) or normal direct bilirubin.

               -  No history of variceal bleeding.

               -  No history of encephalopathy.

               -  No history of ascites

               -  Adequate renal function defined as serum creatinine ≤ 1.5 mg/dL (≤ 130 µmol/L).

               -  Adequate hematological function defined as:

               -  Absolute neutrophil count ≥ 1 x 10³/mm³ ( ≥ 1 x 10^9/L);

               -  Platelets ≥ 80 x 10³/mm³ (≥ 80 x 10^9/L); Platelets ≥ 100 x 10³/mm³ ( ≥ 100 x
                  10^9/L) recommended for the patients who will undergo liver biopsy.

               -  Hemoglobin ≥ 10 g/dL (≥ 100 g/L) (males) or ≥ 9 g/dL (≥ 9 g/L) (females).

               -  Willing and able to undergo a minimum of two liver biopsies (prior to dosing, and
                  after 104 weeks of therapy; only apply to subjects who are enrolled to the sites
                  where liver biopsy is required).

               -  A female is eligible to enter and participate in this study if she is of:

                    1. non-childbearing potential (i.e., physiologically incapable of becoming
                       pregnant, including any female who is pre-menarchal or post-menopausal);

                    2. child-bearing potential with a negative serum pregnancy test at screen, and
                       agrees to one of the following: Complete abstinence from intercourse from 2
                       weeks prior to administration of the study drug, throughout the study, and
                       for a time interval after completion or premature discontinuation from the
                       study to account for elimination of the investigational drug, (a minimum of
                       5 half-lives or longer if the pharmacodynamic profile of the investigational
                       drug warrants a longer time period); or, Female sterilization; or,
                       Sterilization of male partner; or, Implants of levonorgestrel; or,
                       Injectable progestogen; or, Oral contraceptive (combined or progestogen
                       only); or, Any intrauterine device (IUD) with published data showing that
                       the lowest expected failure rate is less than 1% per year (not all IUDs meet
                       this criterion); or, Any other methods with published data showing that the
                       lowest expected failure rate for that method is less than 1% per year; or,
                       Barrier method only if used in combination with any of the above acceptable
                       methods.

               -  Agree not to participate in any other investigational trials or to undertake
                  other HBV systemic antiviral regimens during participation in this study

               -  Able to give written informed consent and comply with the requirements of the
                  study

        Exclusion Criteria:

          -  Any serious or active medical or psychiatric illnesses other than hepatitis B which,
             in the opinion of the investigator, would interfere with patient treatment, assessment
             or compliance with the protocol. This would include, may not limit to, renal, cardiac,
             pulmonary, vascular, neurogenic, digestive, metabolic (diabetes, thyroid disorders,
             adrenal disease), immunodeficiency disorders, active infection or cancer.

          -  Documented evidence of active liver disease due to other causes including co-infection
             hepatitis C (HCV), Subjects who are anti-HCV positive and in whom HCV RNA is
             undetectable are considered to be HCV seropositive and will not eligible; co-infection
             with hepatitis delta (HDV); co-infection with HIV; autoimmune hepatitis (antinuclear
             antibody titre &gt; 1:160)

          -  Clinical signs of decompensated liver disease at baseline. These may include but are
             not limited to:

        serum bilirubin &gt; 2.5 mg/dL (≤ 43 µmol/L) - prothrombin time &gt; 2 second prolonged above ULN

          -  serum albumin &lt; 35g/L

          -  history of ascites, variceal bleeding, or encephalopathy

               -  Alanine aminotransferase (ALT) &gt;10 times ULN at screening or history of acute
                  exacerbation leading to transient decompensation

               -  Hepatocellular carcinoma as evidenced by one of the following:

          -  suspicious foci on ultrasound or radiological examination

          -  - where no positive ultrasound finding, but serum alpha-fetoprotein &gt; 100ng/mL

               -  Active alcohol or drug abuse or history of alcohol or drug abuse considered by
                  the investigator to be sufficient to hinder compliance with treatment,
                  participation in the study or interpretation of results.

               -  Use of immunosuppressive therapy, immunomodulatory therapy (including interferon
                  or thymosin), systemic cytotoxic agents, chronic anti-viral agents excluding
                  lamivudine (e.g. ganciclovir, adefovir dipivoxil, entecavir, famciclovir, FTC,
                  DAPD, LFMAU, HBIg), Chinese herbal medicines known to have activity against HBV
                  within the previous 12 months or during the study; use of agents with effect of
                  ALT reduction (e.g. schisandra agents) during the study

               -  Use of lamivudine within the previous 3 months or during the study

               -  Planned for liver transplantation or previous liver transplantation

               -  Received hepatotoxic drugs (e.g., anabolic steroids, ketaconazole, itraconazole,
                  isoniazid, rifampin, rifabutin) within 2 months prior to study screening or
                  expected to receive these during the course of the study.

               -  Received nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, vancomycin,
                  cidofovir, foscarnet, cis-platinum, pentamidine etc.) or competitors of renal
                  excretion (e.g., probenecid) within 2 months prior to study screening or the
                  expectation that patient will receive any of these during the course of the
                  study.

               -  Receiving systemic (intravenous or oral) steroids, immuno-suppressant therapies
                  or chemotherapeutic agents within 2 months of study screening or expected to
                  receive these agents during the course of the study.

               -  History of hypersensitivity to nucleoside and/or nucleotide analogues.

               -  Inability to comply with study requirements.

               -  Lactating females or females with a positive serum pregnancy test.

               -  Organ or bone marrow transplant recipients.

               -  Previous (or planned) participation in an investigational trial involving
                  administration of investigational compound within 2 months prior to the study
                  screening.

               -  Can not comply with the requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Changsha</city>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chongquin</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jinan</city>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2006</study_first_submitted>
  <study_first_submitted_qc>May 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2006</study_first_posted>
  <results_first_submitted>August 27, 2009</results_first_submitted>
  <results_first_submitted_qc>August 27, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 2, 2009</results_first_posted>
  <last_update_submitted>October 26, 2009</last_update_submitted>
  <last_update_submitted_qc>October 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>adefovir dipivoxil</keyword>
  <keyword>e Antigen negative</keyword>
  <keyword>chronic hepatitis B</keyword>
  <keyword>Chinese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>10 mg Adefovir Dipivoxil (ADV)</title>
          <description>10 mg ADV tablets once daily for 104 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="533"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="490"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>10 mg Adefovir Dipivoxil (ADV)</title>
          <description>10 mg ADV tablets once daily for 104 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="533"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.7" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving HBV DNA ≤300 Copies/mL at Week 104</title>
        <description>Hepatitis B Virus (HBV) DNA level is tested in blood serum by real-time Polymerase Chain Reaction with the lower limit of detection (LLD) as 300 copies/milliliter in a central laboratory.</description>
        <time_frame>Week 104</time_frame>
        <population>Intent-to-Treat (ITT) Population: all HBeAg participants who actually received the study medication at least once. Participants with missing data were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>HBeAg- at Baseline</title>
            <description>All participants who were Hepatitis B e Antigen (HBeAg) negative at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving HBV DNA ≤300 Copies/mL at Week 104</title>
          <description>Hepatitis B Virus (HBV) DNA level is tested in blood serum by real-time Polymerase Chain Reaction with the lower limit of detection (LLD) as 300 copies/milliliter in a central laboratory.</description>
          <population>Intent-to-Treat (ITT) Population: all HBeAg participants who actually received the study medication at least once. Participants with missing data were not included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="488"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBV DNA ≤300 cp/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA &gt; 300 cp/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Histological Improvement After the 104-week Treatment</title>
        <description>Histological improvement (defined as ≥2 point reduction in the Knodell necroinflammation score without worsening fibrosis) was assessed by 2 independent pathologists in the HBeAg-negative participants who underwent 2 sequential liver biopsies at baseline and week 104/withdrawal. The Knodell/histological activity index (HAI) scoring system represents the sum of scores for periportal, bridging necrosis (0–10: none=0, multilobular necrosis=10), interlobular degeneration and focal necrosis (0–4: none=0, marked=4), portal inflammation (0–4: none=0, marked=4), and fibrosis (0–4: none=0, cirrhosis=4)</description>
        <time_frame>Week 104</time_frame>
        <population>HBeAg negative chronic hepatitis B participants who underwent liver biopsy at Week 104</population>
        <group_list>
          <group group_id="O1">
            <title>HBeAg- at Baseline</title>
            <description>All participants who were Hepatitis B e Antigen (HBeAg) negative at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Histological Improvement After the 104-week Treatment</title>
          <description>Histological improvement (defined as ≥2 point reduction in the Knodell necroinflammation score without worsening fibrosis) was assessed by 2 independent pathologists in the HBeAg-negative participants who underwent 2 sequential liver biopsies at baseline and week 104/withdrawal. The Knodell/histological activity index (HAI) scoring system represents the sum of scores for periportal, bridging necrosis (0–10: none=0, multilobular necrosis=10), interlobular degeneration and focal necrosis (0–4: none=0, marked=4), portal inflammation (0–4: none=0, marked=4), and fibrosis (0–4: none=0, cirrhosis=4)</description>
          <population>HBeAg negative chronic hepatitis B participants who underwent liver biopsy at Week 104</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Histological improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No histological change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histological worsening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Histology Scores in HBeAg Negative Participants With Two Sequential Liver Biopsies During the Period of 104 Weeks</title>
        <description>The Knodell/histological activity index (HAI) scoring system that represents the sum of scores for periportal bridging necrosis (0–10: none=0, moderate piecemeal necrosis plus bridging necrosis=5, multilobular necrosis=10); interlobular degeneration and focal necrosis (0–4: none=0, marked=4); portal inflammation (0–4: none=0, marked=4) and fibrosis (0–4: none=0, fibrous portal expansion=1, bridging fibrosis=3, cirrhosis=4) was carried out by two independent pathologists in the HBeAg negative participants with 2 sequential liver biopsies during the period of 104 weeks.</description>
        <time_frame>Baseline to Week 104</time_frame>
        <population>HBeAg negative chronic hepatitis B participants who underwent liver biopsy at Week 48</population>
        <group_list>
          <group group_id="O1">
            <title>HBeAg- at Baseline</title>
            <description>All participants who were Hepatitis B e Antigen (HBeAg) negative at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Histology Scores in HBeAg Negative Participants With Two Sequential Liver Biopsies During the Period of 104 Weeks</title>
          <description>The Knodell/histological activity index (HAI) scoring system that represents the sum of scores for periportal bridging necrosis (0–10: none=0, moderate piecemeal necrosis plus bridging necrosis=5, multilobular necrosis=10); interlobular degeneration and focal necrosis (0–4: none=0, marked=4); portal inflammation (0–4: none=0, marked=4) and fibrosis (0–4: none=0, fibrous portal expansion=1, bridging fibrosis=3, cirrhosis=4) was carried out by two independent pathologists in the HBeAg negative participants with 2 sequential liver biopsies during the period of 104 weeks.</description>
          <population>HBeAg negative chronic hepatitis B participants who underwent liver biopsy at Week 48</population>
          <units>Points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Knodell score at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Knodell score at week 104/withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Necroinflammation score at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Necroinflammation score at week 104/withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrosis score at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fibrosis score at week 104/withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Median Serum HBV DNA Over Time</title>
        <description>The HBV DNA level was tested in blood serum by real-time PCR with the LLD as 300 copies/mL at baseline and Weeks 13, 26, 39, 52, 65, 78, 91, and 104 in a central laboratory.</description>
        <time_frame>Baseline and Weeks 13, 26, 39, 52, 65, 78, 91, and 104</time_frame>
        <population>Intent-to-Treat (ITT) Population: all HBeAg negative participants who actually received the study medication at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>HBeAg- at Baseline</title>
            <description>All participants who were Hepatitis B e Antigen (HBeAg) negative at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Median Serum HBV DNA Over Time</title>
          <description>The HBV DNA level was tested in blood serum by real-time PCR with the LLD as 300 copies/mL at baseline and Weeks 13, 26, 39, 52, 65, 78, 91, and 104 in a central laboratory.</description>
          <population>Intent-to-Treat (ITT) Population: all HBeAg negative participants who actually received the study medication at least once.</population>
          <units>log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum HBV DNA Reduction at week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" lower_limit="-7.0" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum HBV DNA Reduction at week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" lower_limit="-7.1" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum HBV DNA Reduction at week 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" lower_limit="-7.2" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum HBV DNA Reduction at week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" lower_limit="-7.2" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum HBV DNA Reduction at week 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" lower_limit="-7.2" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum HBV DNA Reduction at week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" lower_limit="-7.2" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum HBV DNA Reduction at week 91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" lower_limit="-7.2" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum HBV DNA Reduction at week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" lower_limit="-7.2" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving ALT Normalization at Week 104</title>
        <description>Serum alanine aminotransferase (ALT) normalization was defined as a serum ALT level at or below the upper limit of the normal (ULN) range after a baseline value above the ULN, as determined using central laboratory ranges.</description>
        <time_frame>Week 104</time_frame>
        <population>Intent-to-Treat (ITT) Population: all HBeAg negative participants who actually received the study medication at least once. A total of 435 participants had a baseline ALT value above the ULN.</population>
        <group_list>
          <group group_id="O1">
            <title>HBeAg- at Baseline</title>
            <description>All participants who were Hepatitis B e Antigen (HBeAg) negative at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving ALT Normalization at Week 104</title>
          <description>Serum alanine aminotransferase (ALT) normalization was defined as a serum ALT level at or below the upper limit of the normal (ULN) range after a baseline value above the ULN, as determined using central laboratory ranges.</description>
          <population>Intent-to-Treat (ITT) Population: all HBeAg negative participants who actually received the study medication at least once. A total of 435 participants had a baseline ALT value above the ULN.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="435"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT normalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT non-normalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving HBsAg Loss and HBsAg Seroconversion at Week 104</title>
        <description>HBsAg loss and HBsAg seroconversion (HBsAg loss and HBsAb detected) were assessed for all participants who were HBeAg negative at Weeks 0 and 104. Confirmed HBsAg loss was defined as undetectable HBeAg.</description>
        <time_frame>Week 104</time_frame>
        <population>Intent-to-Treat (ITT) Population: all HBeAg negative participants who actually received the study medication at least once</population>
        <group_list>
          <group group_id="O1">
            <title>HBeAg- at Baseline</title>
            <description>All participants who were Hepatitis B e Antigen (HBeAg) negative at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving HBsAg Loss and HBsAg Seroconversion at Week 104</title>
          <description>HBsAg loss and HBsAg seroconversion (HBsAg loss and HBsAb detected) were assessed for all participants who were HBeAg negative at Weeks 0 and 104. Confirmed HBsAg loss was defined as undetectable HBeAg.</description>
          <population>Intent-to-Treat (ITT) Population: all HBeAg negative participants who actually received the study medication at least once</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBsAg loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg seroconversion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ADV-associated Resistance at Week 104</title>
        <description>Week 104 serum samples from participants who reached a HBV DNA breakthrough were assessed for the development of ADV (Adefovir dipivoxil) mutations (N236T and A181V) in the HBV polymerase. HBV DNA breakthrough was defined as an increase in HBV DNA level by 1 log10 copies/mL or more from the treatment nadir during Weeks 0 to 104.</description>
        <time_frame>Week 104</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg Adefovir Dipivoxil (ADV)</title>
            <description>10 mg ADV tablets once daily for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ADV-associated Resistance at Week 104</title>
          <description>Week 104 serum samples from participants who reached a HBV DNA breakthrough were assessed for the development of ADV (Adefovir dipivoxil) mutations (N236T and A181V) in the HBV polymerase. HBV DNA breakthrough was defined as an increase in HBV DNA level by 1 log10 copies/mL or more from the treatment nadir during Weeks 0 to 104.</description>
          <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBV DNA breakthrough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADV-associated resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving HBV DNA ≤300 Copies/mL Over Time</title>
        <description>Hepatitis B Virus (HBV) DNA level is tested in blood serum by real-time Polymerase Chain Reaction with the lower limit of detection (LLD) as 300 copies/milliliter in a central laboratory.</description>
        <time_frame>Weeks 13, 26, 39, 52, 65, 78, 91, and 104</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once. Missing data were not included in statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>HBeAg- at Baseline</title>
            <description>All participants who were Hepatitis B e Antigen (HBeAg) negative at baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving HBV DNA ≤300 Copies/mL Over Time</title>
          <description>Hepatitis B Virus (HBV) DNA level is tested in blood serum by real-time Polymerase Chain Reaction with the lower limit of detection (LLD) as 300 copies/milliliter in a central laboratory.</description>
          <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once. Missing data were not included in statistical analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBV DNA ≤300 cp/mL, Week 13, n=528</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA ≤300 cp/mL, Week 26, n=525</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA ≤300 cp/mL, Week 39, n=523</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA ≤300 cp/mL, Week 52, n=522</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA ≤300 cp/mL, Week 65, n=514</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA ≤300 cp/mL, Week 78, n=513</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA ≤300 cp/mL, Week 91, n=505</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBV DNA ≤300 cp/mL, Week 104, n=488</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Complete Response at Week 104</title>
        <description>Complete response was defined as an HBV DNA level ≤ 300 copies/mL by the Roche COBAS AMPLICOR HBV MONITOR Test and ALT normalized for two consecutive visits at least 3 months apart.</description>
        <time_frame>Week 104</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg Adefovir Dipivoxil (ADV</title>
            <description>10 mg ADV tablets once daily for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Complete Response at Week 104</title>
          <description>Complete response was defined as an HBV DNA level ≤ 300 copies/mL by the Roche COBAS AMPLICOR HBV MONITOR Test and ALT normalized for two consecutive visits at least 3 months apart.</description>
          <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Protocol-defined Complete Response Over a 104-week Treatment Period</title>
        <description>Time to response was defined as the time to participants achieving protocol-defined complete response at week 104 from baseline. Protocol-defined complete response was an HBV DNA level ≤ 300 copies/mL by Roche COBAS AMPLICOR HBV MONITOR Test and ALT normalized for two consecutive visits at least 3 months apart.</description>
        <time_frame>Baseline to Week 104</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>10 mg Adefovir Dipivoxil (ADV)</title>
            <description>10 mg ADV tablets once daily for 104 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Protocol-defined Complete Response Over a 104-week Treatment Period</title>
          <description>Time to response was defined as the time to participants achieving protocol-defined complete response at week 104 from baseline. Protocol-defined complete response was an HBV DNA level ≤ 300 copies/mL by Roche COBAS AMPLICOR HBV MONITOR Test and ALT normalized for two consecutive visits at least 3 months apart.</description>
          <population>Intent-to-Treat (ITT) Population: all participants who actually received the study medication at least once.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="533"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.6" spread="147.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>10 mg Adefovir Dipivoxil (ADV)</title>
          <description>10 mg ADV tablets once daily for 104 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurilemmoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="533"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

